Detalles de la búsqueda
1.
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Gynecol Oncol
; 166(2): 219-229, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35690498
2.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat
; 187(1): 155-165, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33591468
3.
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Lancet Oncol
; 20(11): 1587-1601, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31575503
4.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
J Clin Oncol
; 41(2): 198-205, 2023 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36332179
5.
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
Clin Cancer Res
; 28(4): 629-636, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887261
6.
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
NPJ Breast Cancer
; 7(1): 57, 2021 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34016993
7.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 7(4): 573-584, 2021 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33480963
Resultados
1 -
7
de 7
1
Próxima >
>>